LOS ALTOS, Calif., Feb. 8 InteKrin Therapeutics Inc announced today that the Company's co-founder and Scientific Advisory Board Chairman, Christos Mantzoros, M.D., DSc., FACP, FACE, has been appointed Professor of Medicine at Harvard Medical School and Professor in Environmental Health at the Harvard School of Public Health.
Dr. Mantzoros is a member of Harvard's Division of Endocrinology, Diabetes, and Metabolism, and is an acknowledged expert in the fields of insulin resistance, body weight regulation, adipokine biology, and energy homeostasis. He has published more than 200 original papers and more than 100 reviews and chapters which have received more than 12,000 citations. He has received several national and international awards and has also been elected a member of The American Society for Clinical Investigation (ASCI).
Dr. Mantzoros, who trained at Harvard, serves as Founding Director of the Human Nutrition Research Unit and as the Clinical Research Overseer at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center. In conjunction with his new appointment, he will also be assuming responsibilities as Chief of Endocrinology and Diabetes at the Greater Boston VA Healthcare System, a system of three hospitals and six outpatient clinics in the greater Boston area which are affiliated with Harvard Medical School.
Dennis M. Lanfear, President and Chief Executive Officer, and Dr. Mantzoros founded InteKrin Therapeutics Inc in 2005. Dr. Mantzoros remains an integral part of InteKrin Therapeutics' management team and regularly advises on scientific matters.
About InteKrin (www.InteKrin.com):
InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.
SOURCE InteKrin Therapeutics Inc